Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06855823
What this trial is testing

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Who this might be right for
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Sun Yat-sen University 33
Early research (Phase 1)Study completedNCT02689453
What this trial is testing

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Who this might be right for
T-Cell Lymphoma RelapsedAdult T-Cell Leukemia (ATL)Peripheral T-Cell Lymphoma (PTCL)+2 more
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)UnknownNCT04052659
What this trial is testing

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Who this might be right for
Peripheral T-cell Lymphoma
Peking University 30
Early research (Phase 1)Study completedNCT02567656
What this trial is testing

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Who this might be right for
Lymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous
Rhizen Pharmaceuticals SA 58
Early research (Phase 1)Study completedNCT01435863
What this trial is testing

SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-cell Lymphoma
Solasia Pharma K.K. 17
Testing effectiveness (Phase 2)WithdrawnNCT03999658
What this trial is testing

STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Who this might be right for
Peripheral T Cell LymphomaDiffuse Large B Cell LymphomaBiliary Tract Cancer+1 more
Sorrento Therapeutics, Inc.
Testing effectiveness (Phase 2)Study completedNCT03192202
What this trial is testing

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Who this might be right for
Lymphoma, T-Cell, Cutaneous
Ahmed Sawas 18
Testing effectiveness (Phase 2)Ended earlyNCT03075553
What this trial is testing

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmHepatosplenic T-Cell LymphomaHTLV-1 Infection+14 more
Mayo Clinic 12
Testing effectiveness (Phase 2)Looking for participantsNCT05934513
What this trial is testing

GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc. 95
Large-scale testing (Phase 3)WithdrawnNCT03355768
What this trial is testing

Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Who this might be right for
Lymphoma, T-Cell, Peripheral
Jennifer Amengual
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07279584
What this trial is testing

Golidocitinib Combined With GemOx in RR PTCL

Who this might be right for
Peripheral T-cell Lymphomas (PTCL)
Ruijin Hospital 31
Testing effectiveness (Phase 2)Study completedNCT04105010
What this trial is testing

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

Who this might be right for
Relapsed or Refractory Peripheral T Cell Lymphoma
Dizal Pharmaceuticals 171
Early research (Phase 1)Ended earlyNCT02978235
What this trial is testing

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Who this might be right for
Multiple MyelomaNonHodgkin Lymphoma
Taiho Oncology, Inc. 11
Testing effectiveness (Phase 2)Study completedNCT03493451
What this trial is testing

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Who this might be right for
Peripheral T Cell LymphomaPTCLExtranodal NK/T-cell Lymphoma+16 more
BeiGene 77
Large-scale testing (Phase 3)Study completedNCT03349333
What this trial is testing

A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL

Who this might be right for
Refractory Peripheral T-Cell LymphomaRelapsed T-Cell Lymphoma
Mundipharma (China) Pharmaceutical Co. Ltd 85
Testing effectiveness (Phase 2)Looking for participantsNCT07018752
What this trial is testing

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Who this might be right for
Peripheral T Cells Lymphoma (PTCL)
The Lymphoma Academic Research Organisation 49
Testing effectiveness (Phase 2)Looking for participantsNCT06925464
What this trial is testing

CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

Who this might be right for
T-Cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital 36
Early research (Phase 1)Looking for participantsNCT07192471
What this trial is testing

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

Who this might be right for
T-cell NHL (PTCL or CTCL)
Kyowa Kirin, Inc. 72
Testing effectiveness (Phase 2)Temporarily pausedNCT06761677
What this trial is testing

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Who this might be right for
Relapsed or Refractory Lymphoma Including ENKL
SymBio Pharmaceuticals 43
Testing effectiveness (Phase 2)Study completedNCT01994382
What this trial is testing

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Who this might be right for
Follicular Lymphoma (FL/Indolent NHL)Aggressive NHL (a NHL)Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)+2 more
Alexion Pharmaceuticals, Inc. 260
Next Page